Vascular endothelial growth factor and insulin growth factor as an underlying paracrine action of mesenchymal stem cells transfused for the regeneration of stage II and III chronic kidney disease

Saadi, Gamal; Ansary, Mervat El; Hassaballa, May; Roshdy, Mona; el-Aziz, E. Abd; Bishai, Irene; Mohamed, Samah; Gaafary, Mahmoud El; Zidan, M.

doi:10.4103/1110-9165.179198

Cited by 4 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chart 1: Representing the differences between studied groups in proinflammatory Cytokines production gene (p<0.05). been restored [28]. Other results stated that MSCs administration to rats with acute kidney injury significantly restored renal functional parameters and hastened functional recovery [27,29,30].…”

Section: Comparison Among Different Groupsmentioning

confidence: 97%

Bone Marrow Derived Mesenchymal Stem Cell Therapy in Induced Acute Renal Injury in Adult Male Albino Rats

El-Wahab¹,

A²,

A³

et al. 2017

J Cytol Histol

View full text Add to dashboard Cite

Background and objectives: Acute renal injury (ARI) is a serious clinical problem without established regimen for treatment. Mesenchymal stem cells (MSCs) are undifferentiated cells that can differentiate and give rise to other cell types. The aim of the present work is to study the possible therapeutic role of MSCs in the treatment of the deleterious changes occurred in renal cortex and medulla of adult male albino rat model of ischemia/reperfusion (I/R) ARI.Material and methods: Forty adult male albino rats were used in this study. Animals were divided into four groups, 10 animals for each group. Group I is control sham-operated group. Three experimental groups were all subjected to I/R injury by clamping both renal pedicles for 40 min. These animals were further divided into three subgroups. Group II is non-MSC treated group. Group III (MSC treated group (local injection)): I/R animals received bromodeoxyuridine labeled BM-MSCs locally in renal cortex immediately after removal of the clamps and confirmation of reflow. Group IV (MSC treated group (systemic injection)): I/R animals that received single intravenous injection of bromdeoxyouridine labeled BM-MSCs in tail vein immediately after removal of the clamps and confirmation of reflow. Animals were sacrificed after 3 days of intervention. Serological measurements included serum urea and creatinine. Kidney specimens were processed for H&E, PCNA and Caspase-3. Real time RT-PCR study was done for TNF α and IL-6 gene expression.Results: Cortical and medullary renal tissue exhibited marked improvement histologically and serologically after MSCs treatment. The improvement was more obvious in case of systemic treatment. Conclusion:The present study shows the ability of MSCs to repair the structural and functional renal damage after I/R, Systemic route is more beneficial than local route. This may pave the future for therapeutic use of MSCs in the treatment of acute renal injury.

show abstract

Section: Comparison Among Different Groupsmentioning

confidence: 97%

Bone Marrow Derived Mesenchymal Stem Cell Therapy in Induced Acute Renal Injury in Adult Male Albino Rats

El-Wahab¹,

A²,

A³

et al. 2017

J Cytol Histol

View full text Add to dashboard Cite

show abstract

“…In patients suffering from chronic diabetic nephropathy, allogeneic transplantation of MSCs demonstrated renal function improvements compared to placebo ( 60 ). The effect can be attributed to the paracrine secretion of VEGF and IGF-1 needed for angiogensis and tissue regeneration, and to the anti-inflammatory effect that controls the overactivated immune response that accompanies most CKD before significant sclerosis develops ( 59 , 61 ).…”

Section: Treatment With Mesenchymal Stromal Cells In Acute Kidney Injmentioning

confidence: 99%

Mesenchymal Stromal Cell Uses for Acute Kidney Injury—Current Available Data and Future Perspectives: A Mini-Review

Zilberman-Itskovich

Efrati

2020

Front. Immunol.

View full text Add to dashboard Cite

There is growing evidence concerning the potential use of mesenchymal stromal cells (MSCs) for different tissue injuries. Initially, the intended physiological use of MSCs was due to their ability to differentiate and replace damaged cells. However, MSCs have multiple effects, including being able to significantly modulate immunological responses. MSCs are currently being tested for neurodegenerative diseases, graft vs. host disease, kidney injury, and other chronic unremitting tissue damage. Using MSCs in acute tissue damage is only now being studied. Acute kidney injury (AKI) is a common cause of morbidity and mortality. After the primary insult, overactivation of the immune system culminates in additional secondary potentially permanent kidney damage. MSCs have the potential to ameliorate the secondary damage, and recent studies have shed important light on their mechanisms of action. This article summarizes the basics of MSCs therapy, the newly discovered mechanisms of action, and their potential application in the setting of AKI.

show abstract

Bone marrow–mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up

et al. 2018

View full text Add to dashboard Cite

Vascular endothelial growth factor and insulin growth factor as an underlying paracrine action of mesenchymal stem cells transfused for the regeneration of stage II and III chronic kidney disease

Cited by 4 publications

References 1 publication

Bone Marrow Derived Mesenchymal Stem Cell Therapy in Induced Acute Renal Injury in Adult Male Albino Rats

Bone Marrow Derived Mesenchymal Stem Cell Therapy in Induced Acute Renal Injury in Adult Male Albino Rats

Mesenchymal Stromal Cell Uses for Acute Kidney Injury—Current Available Data and Future Perspectives: A Mini-Review

Bone marrow–mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up

Contact Info

Product

Resources

About